TW200423930A - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors Download PDF

Info

Publication number
TW200423930A
TW200423930A TW093103358A TW93103358A TW200423930A TW 200423930 A TW200423930 A TW 200423930A TW 093103358 A TW093103358 A TW 093103358A TW 93103358 A TW93103358 A TW 93103358A TW 200423930 A TW200423930 A TW 200423930A
Authority
TW
Taiwan
Prior art keywords
group
alkyl
alkoxy
phenyl
optionally substituted
Prior art date
Application number
TW093103358A
Other languages
English (en)
Chinese (zh)
Inventor
James Patrick Dunn
Joan Heather Hogg
Taraneh Mirzadegan
Steven Swallow
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200423930A publication Critical patent/TW200423930A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093103358A 2003-02-18 2004-02-12 Non-nucleoside reverse transcriptase inhibitors TW200423930A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44797403P 2003-02-18 2003-02-18

Publications (1)

Publication Number Publication Date
TW200423930A true TW200423930A (en) 2004-11-16

Family

ID=32908518

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093103358A TW200423930A (en) 2003-02-18 2004-02-12 Non-nucleoside reverse transcriptase inhibitors

Country Status (17)

Country Link
US (1) US7241794B2 (https=)
EP (1) EP1597235B1 (https=)
JP (1) JP4608480B2 (https=)
KR (1) KR100776093B1 (https=)
CN (1) CN100389109C (https=)
AR (1) AR043195A1 (https=)
AT (1) ATE370124T1 (https=)
BR (1) BRPI0407591A (https=)
CA (1) CA2515151C (https=)
CL (1) CL2004000270A1 (https=)
DE (1) DE602004008227T2 (https=)
ES (1) ES2291854T3 (https=)
MX (1) MXPA05008748A (https=)
PL (1) PL378556A1 (https=)
RU (1) RU2305680C2 (https=)
TW (1) TW200423930A (https=)
WO (1) WO2004074257A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011922A (es) * 2003-05-07 2006-02-17 Pfizer Prod Inc Ligandos del receptor de cannabinoides y sus usos.
US8022225B2 (en) 2004-08-04 2011-09-20 Taisho Pharmaceutical Co., Ltd Triazole derivative
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
RU2409570C2 (ru) 2006-02-03 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. Производные триазола
CN101415687B (zh) 2006-02-06 2012-02-08 大正制药株式会社 鞘氨醇-1-磷酸结合抑制物质
NZ570495A (en) * 2006-02-14 2011-10-28 Ihara Chemical Ind Co Process for production of 5-alkoxy-4-hydroxymethylpyrazole compound
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
RU2451676C2 (ru) * 2006-08-16 2012-05-27 Ф.Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
WO2008119662A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
US8048898B2 (en) 2007-08-01 2011-11-01 Taisho Pharmaceutical Co., Ltd Inhibitor of binding of S1P1
WO2009080534A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
HUE025336T2 (en) 2010-03-30 2016-03-29 Merck Canada Inc Non-nucleoside reverse transcriptase inhibitors
AU2011277426B2 (en) 2010-07-15 2015-04-23 Sumitomo Pharma Co., Ltd. Pyrazole compound
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
MX2014014911A (es) 2012-06-20 2015-05-15 Univ Vanderbilt Análogos de alcoxi pirazol bicíclico sustituido como moduladores alostéricos de receptores de mglur5.
WO2013192343A1 (en) 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
PL3125894T3 (pl) 2014-04-01 2021-02-08 Merck Sharp & Dohme Corp. Proleki inhibitorów odwrotnej transkryptazy hiv
EP3194386A2 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
BR112017018140A2 (pt) * 2015-03-19 2018-04-10 Du Pont ?composto, composição fungicida e método de controle de doenças de plantas?
EP3478665A1 (en) * 2016-06-29 2019-05-08 Esteve Pharmaceuticals, S.A. Pyrazole derivatives having activity against pain
CN110818636A (zh) * 2019-11-29 2020-02-21 河北科技大学 一种化合物或其盐及其应用和合成方法
CN115677585B (zh) * 2022-10-31 2024-03-19 上海群力化工有限公司 一种甲醛吡唑衍生物的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0786455T3 (da) 1994-09-26 2004-03-29 Shionogi & Co Imidazolderivater
DE19734664A1 (de) * 1997-08-11 1999-02-18 Bayer Ag (Hetero)Aryloxypyrazole
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
GB0028484D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
IL157875A0 (en) * 2001-04-10 2004-03-28 Pfizer Pyrazole derivatives for treating hiv
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives

Also Published As

Publication number Publication date
DE602004008227T2 (de) 2008-05-15
CL2004000270A1 (es) 2005-02-04
CA2515151A1 (en) 2004-09-02
CA2515151C (en) 2010-11-30
AR043195A1 (es) 2005-07-20
KR100776093B1 (ko) 2007-11-15
PL378556A1 (pl) 2006-05-02
RU2305680C2 (ru) 2007-09-10
EP1597235B1 (en) 2007-08-15
WO2004074257A1 (en) 2004-09-02
ES2291854T3 (es) 2008-03-01
RU2005128832A (ru) 2006-04-27
US7241794B2 (en) 2007-07-10
CN1751028A (zh) 2006-03-22
AU2004213134A1 (en) 2004-09-02
JP2006515339A (ja) 2006-05-25
MXPA05008748A (es) 2005-09-20
JP4608480B2 (ja) 2011-01-12
DE602004008227D1 (de) 2007-09-27
EP1597235A1 (en) 2005-11-23
ATE370124T1 (de) 2007-09-15
CN100389109C (zh) 2008-05-21
BRPI0407591A (pt) 2006-02-14
KR20050105471A (ko) 2005-11-04
US20040192666A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
TW200423930A (en) Non-nucleoside reverse transcriptase inhibitors
RU2578608C2 (ru) Новое имидазооксазиновое соединение или его соль
US6593337B1 (en) Tricyclic compounds useful as HIV reverse transcriptase inhibitors
CA2282593A1 (en) Indazoles of cyclic ureas useful as hiv protease inhibitors
TW200819440A (en) Benzotriazole kinase modulators
TW201002683A (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
SK137899A3 (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors
Kumar et al. Synthesis and in–vitro anti–HIV–1 evaluation of novel pyrazolo [4, 3–c] pyridin–4–one derivatives
US20040133002A1 (en) Pyrazole derivatives
CA2983668A1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
JP2004532276A (ja) Hiv逆転写酵素阻害剤としてのピラゾール誘導体
EP1551828B1 (en) Pyrazole derivatives
TW201100404A (en) Heterocyclic antiviral compounds
US9249148B2 (en) Tris(hetero)arylpyrazoles and use thereof
US20050054707A1 (en) Pyrazole derivatives
US20250179033A1 (en) New antiviral triazole derivatives, their synthesis and their use for treatment of mammalian viral infections
EP1546132A1 (en) Pyrazole derivatives as reverse transcriptase inhibitors
AU2004213134B2 (en) Non-nucleoside reverse transcriptase inhibitors
ES2305563T3 (es) Derivados de pirazol y su uso como agentes terapeuticos para enfermedades mediadas por el vih.
US7230025B2 (en) Pyrazole derivatives